Stéphanie Grosse

Title: Stéphanie Grosse: Innovator in Immunotherapy

Introduction

Stéphanie Grosse is a notable inventor based in Saint-Cyr sur Morin, France. He has made significant contributions to the field of immunotherapy, particularly in the engineering of T-cells for cancer treatment. His innovative approaches aim to enhance the effectiveness of immunotherapy while minimizing the risks associated with immunosuppressive drugs.

Latest Patents

Stéphanie Grosse holds a patent for "Methods for engineering allogeneic and immunosuppressive resistant T cell for immunotherapy." This invention focuses on developing engineered T-cells that are both non-alloreactive and resistant to immunosuppressive agents. The methods involve modifying T-cells by inactivating genes that encode targets for immunosuppressive agents and T-cell receptors, specifically genes encoding CD52 and TCR. The use of specific rare cutting endonucleases, particularly TALE-nucleases, allows for precise targeting of key genes in T-cells sourced from donors or cultured primary cells. This groundbreaking invention paves the way for standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.

Career Highlights

Stéphanie Grosse is associated with Cellectis, a company known for its pioneering work in gene editing and immunotherapy. His role at Cellectis has allowed him to further his research and development efforts in the field, contributing to advancements that could transform cancer treatment.

Collaborations

Stéphanie has collaborated with notable colleagues such as Roman Galetto and Agnès Gouble. Their combined expertise has fostered an environment of innovation and progress in the field of immunotherapy.

Conclusion

Stéphanie Grosse's contributions to immunotherapy through his patented methods for engineering T-cells represent a significant advancement in cancer treatment. His work continues to inspire and pave the way for future innovations in the field.